X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with PLETHICO PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs PLETHICO PHARMA - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA PLETHICO PHARMA ASTRAZENECA PHARMA/
PLETHICO PHARMA
 
P/E (TTM) x 103.7 -1.1 - View Chart
P/BV x 14.8 0.0 88,158.1% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ASTRAZENECA PHARMA   PLETHICO PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
PLETHICO PHARMA
Mar-14
ASTRAZENECA PHARMA/
PLETHICO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,285395 325.4%   
Low Rs63431 2,025.6%   
Sales per share (Unadj.) Rs189.6604.4 31.4%  
Earnings per share (Unadj.) Rs-0.232.5 -0.6%  
Cash flow per share (Unadj.) Rs3.851.3 7.5%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs68.6473.6 14.5%  
Shares outstanding (eoy) m25.0034.08 73.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.10.4 1,435.4%   
Avg P/E ratio x-4,712.76.6 -71,826.5%  
P/CF ratio (eoy) x249.64.2 6,011.3%  
Price / Book Value ratio x14.00.5 3,106.4%  
Dividend payout %00-   
Avg Mkt Cap Rs m23,9887,262 330.3%   
No. of employees `0001.6NA-   
Total wages/salary Rs m1,6051,596 100.5%   
Avg. sales/employee Rs Th3,040.2NM-  
Avg. wages/employee Rs Th1,029.2NM-  
Avg. net profit/employee Rs Th-3.3NM-  
INCOME DATA
Net Sales Rs m4,74020,598 23.0%  
Other income Rs m92386 23.8%   
Total revenues Rs m4,83220,984 23.0%   
Gross profit Rs m-1302,818 -4.6%  
Depreciation Rs m101642 15.8%   
Interest Rs m01,593 0.0%   
Profit before tax Rs m-139969 -14.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m5-138 -3.7%   
Profit after tax Rs m-51,107 -0.5%  
Gross profit margin %-2.713.7 -20.0%  
Effective tax rate %-3.7-14.3 25.6%   
Net profit margin %-0.15.4 -2.0%  
BALANCE SHEET DATA
Current assets Rs m2,72618,877 14.4%   
Current liabilities Rs m2,43511,896 20.5%   
Net working cap to sales %6.133.9 18.1%  
Current ratio x1.11.6 70.6%  
Inventory Days Days7436 205.2%  
Debtors Days Days41198 20.6%  
Net fixed assets Rs m1,0359,861 10.5%   
Share capital Rs m50341 14.7%   
"Free" reserves Rs m94212,331 7.6%   
Net worth Rs m1,71616,139 10.6%   
Long term debt Rs m04,706 0.0%   
Total assets Rs m4,15633,146 12.5%  
Interest coverage xNM1.6-  
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.10.6 183.5%   
Return on assets %-0.18.1 -1.5%  
Return on equity %-0.36.9 -4.3%  
Return on capital %012.3 0.0%  
Exports to sales %5.721.4 26.7%   
Imports to sales %6.515.2 42.4%   
Exports (fob) Rs m2704,402 6.1%   
Imports (cif) Rs m3063,136 9.8%   
Fx inflow Rs m3754,402 8.5%   
Fx outflow Rs m4703,184 14.8%   
Net fx Rs m-961,219 -7.8%   
CASH FLOW
From Operations Rs m-82,437 -0.3%  
From Investments Rs m-146-6,265 2.3%  
From Financial Activity Rs m8622,490 34.6%  
Net Cashflow Rs m709-1,337 -53.0%  

Share Holding

Indian Promoters % 0.0 82.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 4.3 7.0%  
FIIs % 15.7 5.5 285.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 7.5 121.3%  
Shareholders   12,856 10,665 120.5%  
Pledged promoter(s) holding % 0.0 85.7 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   WYETH LTD  IPCA LABS  NATCO PHARMA  SUN PHARMA  PIRAMAL ENTERPRISES  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Feb 19, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS